JP2023539125A - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP2023539125A
JP2023539125A JP2023512139A JP2023512139A JP2023539125A JP 2023539125 A JP2023539125 A JP 2023539125A JP 2023512139 A JP2023512139 A JP 2023512139A JP 2023512139 A JP2023512139 A JP 2023512139A JP 2023539125 A JP2023539125 A JP 2023539125A
Authority
JP
Japan
Prior art keywords
compound
disorders
disorder
compound according
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512139A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022040545A5 (https=
JP2023539125A5 (https=
Inventor
ポン，リ
イー デイビス，ロバート
チャオ，ユープー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2023539125A publication Critical patent/JP2023539125A/ja
Publication of JPWO2022040545A5 publication Critical patent/JPWO2022040545A5/ja
Publication of JP2023539125A5 publication Critical patent/JP2023539125A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2023512139A 2020-08-20 2021-08-20 有機化合物 Pending JP2023539125A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068222P 2020-08-20 2020-08-20
US63/068,222 2020-08-20
PCT/US2021/046935 WO2022040545A1 (en) 2020-08-20 2021-08-20 Organic compounds

Publications (3)

Publication Number Publication Date
JP2023539125A true JP2023539125A (ja) 2023-09-13
JPWO2022040545A5 JPWO2022040545A5 (https=) 2024-08-28
JP2023539125A5 JP2023539125A5 (https=) 2024-08-28

Family

ID=80350596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512139A Pending JP2023539125A (ja) 2020-08-20 2021-08-20 有機化合物

Country Status (4)

Country Link
US (1) US20230416300A1 (https=)
EP (1) EP4200312A4 (https=)
JP (1) JP2023539125A (https=)
WO (1) WO2022040545A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
AU2019406803B2 (en) 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
CN117715641A (zh) * 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
CN116606341A (zh) * 2022-07-28 2023-08-18 上海醇健实业发展有限公司 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物
EP4650359A1 (en) * 2022-07-28 2025-11-19 Hunan Kyf Pharmaceutical. Co., Ltd. Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof
WO2024059608A1 (en) * 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
WO2024230797A1 (zh) * 2023-05-11 2024-11-14 上海枢境生物科技有限公司 甾体类化合物、制备方法及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510701A (ja) * 1994-02-14 1997-10-28 コセンシス・インコーポレイテッド Ｇａｂａ受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類
JP2002543218A (ja) * 1999-04-29 2002-12-17 パーデュー ファーマ リミテッド 麻酔活性を有する、３α−ヒドロキシ−３βメトキシメチル−２１−複素環式置換ステロイド
JP2017531019A (ja) * 2014-10-16 2017-10-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP3229350B1 (en) * 2016-04-08 2021-06-23 Black & Decker Inc. Brushless motor for a power tool
EP3720867A1 (en) * 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
EP3728284B1 (en) * 2017-12-22 2024-08-21 Sage Therapeutics, Inc. 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
AU2019406803B2 (en) * 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510701A (ja) * 1994-02-14 1997-10-28 コセンシス・インコーポレイテッド Ｇａｂａ受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類
JP2002543218A (ja) * 1999-04-29 2002-12-17 パーデュー ファーマ リミテッド 麻酔活性を有する、３α−ヒドロキシ−３βメトキシメチル−２１−複素環式置換ステロイド
JP2017531019A (ja) * 2014-10-16 2017-10-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. PHARM. SCI., vol. 64, JPN6014001782, 1975, pages 367 - 391, ISSN: 0005683323 *
JOURNAL OF HIGH TECHNOLOGY LAW, JPN6015005662, 2009, pages 22 - 74, ISSN: 0005683322 *
NATURE, vol. ４５８, JPN6014001781, 19 May 2009 (2009-05-19), pages ２６９, ISSN: 0005683324 *

Also Published As

Publication number Publication date
EP4200312A1 (en) 2023-06-28
US20230416300A1 (en) 2023-12-28
WO2022040545A1 (en) 2022-02-24
EP4200312A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
JP2023539125A (ja) 有機化合物
CN113226326B (zh) 有机化合物
AU2017238858A1 (en) Methods of using (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
AU2016235534A1 (en) Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CA3182354A1 (en) Methyl 2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1h-cyclopenta[b]pyridine-3-carboxylates and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylates as cav1.2 activators
JP2022523355A (ja) 神経障害の処置のための重水素化キサノメリンの化合物及び方法
CN114206899A (zh) 3-羟基-5-孕烷-20-酮衍生物及其用途
MX2011006791A (es) Compuestos de metodos para el tratamiento de dolor y otras enfermedades.
JP7750582B2 (ja) 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途
JP2021519276A (ja) Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用
CN111201016A (zh) 针对情绪疾患的新型γ氨基丁酸A型受体调节剂
RU2809023C2 (ru) Органические соединения
EP4165048B1 (en) Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4- b]pyridine-3-carboxylate compounds as cav1.2 activators
HK40058207A (en) Organic compounds
HK40058207B (zh) 有机化合物
MXPA06013484A (es) Metabolitos de (+)-(2s, 3s)-3-(2- metoxi-5- trifluorometoxibencilamino) -2-fenil- piperidina.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260120